

1 **Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations.**

2
3 Dustin Flanagan¹, Nick Barker^{2,3,4}, Natasha S. Di Costanzo⁵, Elizabeth A. Mason⁶, Austin Gurney⁷,
4 Valerie S. Meniel⁸, Sarah Koushyar⁸, Chloe R. Austin⁸, Helen B. Pearson⁸, Alex Boussioutas⁵,
5 Hans Clevers⁹, Toby J. Phesse^{1,8*#}, Elizabeth Vincan^{1,10*#}.

6
7 ¹University of Melbourne & Victorian Infectious Diseases Reference Laboratory, Doherty Institute
8 of Infection and Immunity, Melbourne, VIC 3010, Australia

9 ²Institute of Medical Biology, Singapore 138648, Singapore

10 ³MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH8 9YL, UK

11 ⁴NTU School of Biological Sciences, Singapore 639798, Singapore

12 ⁵Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia

13 ⁶University of Melbourne, Department of Anatomy and Neuroscience, Melbourne, VIC 3010,
14 Australia

15 ⁷OncoMed Pharmaceuticals Inc., Redwood City, California 94063, USA

16 ⁸European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK

17 ⁹Hubrecht Institute for Developmental Biology and Stem Cell Research, 3584CT Utrecht,
18 Netherlands

19 ¹⁰School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA 6845, Australia

20 * Authors contributed equally.

21
22 **Running title:** Targeting Wnt/Frizzled-7 signaling reduces gastric cancer.

23
24 **Keywords:** Frizzled-7, Wnt signaling, Gastric cancer, Targeted therapies

25
26 **Funding:** Funding is gratefully acknowledged from the following; National Health and Medical
27 Research Council of Australia (NHMRC, 566679 and APP1099302 awarded to E. Vincan/T.J.
28 Phesse/N. Barker), Melbourne Health project grants (605030 and PG-002 awarded to E.
29 Vincan/T.J. Phesse/N. Barker/H. Clevers), Medical Research Council (MR/R026424/1 to T.J.
30 Phesse), and Early career researcher grant (GIA-033 awarded to D.J. Flanagan), Cancer Council
31 of Victoria project grants (CCV, APP1020716 awarded to E. Vincan/T.J. Phesse/N. Barker), CCV
32 Fellowship awarded to D.J. Flanagan and Cardiff University/CMU Research Fellowship awarded
33 to T.J. Phesse.

35 **Correspondence:** #Corresponding authors; Toby Phesse. Email; phesset@cardiff.ac.uk. Tel.
36 +44 (0)2920688495 And Elizabeth Vincan, email; e.vincan@unimelb.edu.au. Tel. +61393429348

37

38 **Disclosures:** Austin Gurney has ownership interests, including patents on the OMP-18R5
39 compound used in this study through OncoMed Pharmaceuticals. The remaining authors declare
40 no conflict of interest.

41

42 **Word count:** 4199

43

44 **Number of figures and tables:** 6 main figures, 7 supplemental figures, 1 supplemental table

45

46 **Abstract**

47 A subset of gastric cancer (GC) patients have mutations in genes that participate in or regulate
48 Wnt signaling at the level of ligand (Wnt) receptor (Fzd) binding. Moreover, increased Fzd
49 expression is associated with poor clinical outcome. Despite these findings, there are no in vivo
50 studies investigating the potential of targeting Wnt receptors for treating GC, and the specific Wnt
51 receptor transmitting oncogenic Wnt signaling in GC is unknown. Here we use inhibitors of
52 Wnt/Fzd (OMP-18R5/Vantictumab) and conditional gene deletion to test the therapeutic potential
53 of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and ex vivo
54 organoid cultures. Pharmacological targeting of Fzd inhibited the growth of gastric adenomas in
55 vivo. We identified Fzd7 to be the predominant Wnt receptor responsible for transmitting Wnt
56 signaling in human gastric cancer cells and mouse models of GC, whereby Fzd7-deficient cells
57 were retained in gastric adenomas but were unable to respond to Wnt signals and consequently
58 failed to proliferate. Genetic deletion of Fzd7 or treatment with Vantictumab was sufficient to inhibit
59 the growth of gastric adenomas with or without mutations to Apc. Vantictumab is currently in
60 phase Ib clinical trials for advanced pancreatic, lung, and breast cancer. Our data extend the
61 scope of patients that may benefit from this therapeutic approach as we demonstrate that this
62 drug will be effective in treating gastric cancer patients regardless of Apc mutation status.

63

64 **Statement of significance**

65 The Wnt receptor Fzd7 plays an essential role in gastric tumorigenesis irrespective of Apc
66 mutation status therefore targeting Wnt/Fzd7 may be of therapeutic benefit to gastric cancer
67 patients.

68

69 Introduction

70 Gastric cancer (GC) is a common malignancy, ranking in the top 4 of global cancer incidence [1].
71 Often due to advanced stage diagnosis, gastric cancer patients have a very poor 5-year survival
72 rate [1]. This highlights a desperate need for novel clinical treatments as there are very few
73 approved targeted therapies for GC [2, 3]. Gastric cancer is divided histologically into two groups;
74 intestinal-type and diffuse-type, with intestinal-type being more prevalent. Members of the cell-
75 surface Frizzled (Fzd) receptor family are deregulated or overexpressed in several cancer types,
76 including GC [4]. Wnts are lipid-modified glycoproteins that initiate signal transduction by binding
77 to Fzd via a palmitate group, which is appended by the palmitoyltransferase Porcupine (PORCN)
78 [5, 6]. Wnts also bind cell surface co-receptors, such as Lrp5/6, forming a ternary complex [7].
79 Formation of the Wnt-receptor complex leads to inhibition of a multiprotein 'destruction complex'
80 comprised of Axin, glycogen synthase kinase-3 (GSK3), calcium kinase-1 (CK1) and
81 adenomatous polyposis coli (APC), which targets β -catenin for proteosomal degradation. Newly
82 synthesised cytoplasmic β -catenin can now escape degradation, accumulate and translocate to
83 the nucleus, where it forms a transcriptionally active complex with T-cell factor (TCF)/lymphoid
84 enhancing factor (LEF) family of transcription factors to induce Wnt target gene transcription [8].
85 However, deregulated Wnt signaling can initiate cell transformation and subsequent
86 carcinogenesis [8].

87

88 Furthermore, several Wnt/Fzd antagonists [9] are epigenetically silenced through promoter hyper-
89 methylation, including *DKK3* (67.6% of gastric tumors [10]), *sFRP1* (91%), *sFRP2* (96%), *sFRP5*
90 (65%) [11], whilst others such as the E3 ligase *RNF43*, which regulates Fzd turnover on the cell
91 surface [12], are mutated in 54% and 4.8% of microsatellite instable (MSI) and microsatellite
92 stable (MSS) gastric tumors, respectively [13]. Exogenous re-introduction of sFRP or DKK can
93 significantly reduce gastric tumor burden in *APC* or *β -catenin*-mutant gastric cancer cells by
94 attenuating Wnt signaling [11, 14]. Critically, this provides proof-of-principle that modulation of
95 ligand/receptor signaling components can further regulate Wnt signaling irrespective of
96 downstream mutations that constitutively activate the pathway, which has been reported in
97 colorectal cancer cells [15-18]. Together, these data strongly implicate a role for Wnt/Fzd in GC
98 which could be exploited for targeted therapy.

99

100 We recently demonstrated that Frizzled-7 (Fzd7) regulates stem cell function in the gastric and
101 intestinal epithelium [19, 20]. In addition, *FZD7* is abundantly expressed in human gastric cancer
102 tissue [21-23], which is also associated with poor patient outcome [24]. Despite compelling

103 evidence implicating Fzd receptors in GC, there has been no formal investigation of the
104 therapeutic benefit of targeting Fzd receptors in GC *in vivo*. These types of *in vivo* studies are
105 crucial to fully understand the potential of novel therapeutic strategies due to the complex cellular
106 and molecular interactions of a tumor, which can directly inform clinical trials and cannot be
107 replicated *in vitro*. Our results demonstrate that Fzd receptors, specifically *Fzd7*, are rate-limiting
108 for the growth of gastric adenomas with or without *Apc* mutations *in vivo*. These findings have
109 significant clinical utility as targeted Fzd therapeutics (OMP-18R5/Vantictumab), currently being
110 tested in other solid cancer types (<http://www.oncomed.com/Pipeline>), can now be extended to
111 GC patients with and without *APC* mutations.

112

113 **Materials and Methods**

114 **Mice**

115 The *Tff1Cre^{ERT2}* [25], *Fzd7^{fl/fl}* [20], *Apc⁵⁸⁰* (*Apc^{fl/fl}*) [26], *c-Myc^{fl/fl}* [27], *Rosa26LacZ* [28] and *gp130^{F/F}*
116 [29] are previously described. Mice were interbred to generate compound mice with appropriate
117 alleles on an inbred C57Bl/6 genetic background. Mice were co-housed using appropriate
118 littermates as controls. All animal experiments were approved by the Animal Ethics Committee,
119 Office for Research Ethics and Integrity, University of Melbourne.

120

121 **Treatments**

122 *In vivo* Cre induction was performed in 8-10 week old mice with a single daily intraperitoneal (ip)
123 injection of 2mg of tamoxifen/mouse/day over four consecutive days. *gp130^{F/F}* mice aged 8-9
124 weeks were injected ip with 20mg/kg of OMP-18R5 (OncoMed) or vehicle control
125 (2.5%DMSO+IgG) twice weekly over the course of 30 days at which point animals were sacrificed
126 and tissues harvested.

127

128 **Tumor xenografts**

129 A total of 4×10^6 cells in 100 μ l of PBS were injected subcutaneously into the hind flank of 6-8 week
130 old nude mice (*nu(ncr)-foxn1 nu/nu*). 7 mice were used for each cohort which were treated with
131 20mg/kg OMP-18R5 or vehicle control (2.5%DMSO+IgG) once tumors were palpable, five days
132 following injection of cells. Xenografts were measured with calipers twice a week to monitor tumor
133 growth.

134

135

136

137 **Tissue collection and histological analysis**

138 Mouse stomachs were isolated, flushed with PBS, fixed overnight at 4°C in 10% neutral buffered
139 formalin (NBF) and processed for immunohistochemistry and immunofluorescence as we
140 previously described [20, 30, 31], with antibodies used on Table S2.

141

142 **Isolation and culture of normal and tumor organoids**

143 Organoids were cultured from mouse stomachs as previously described [31]. Adenomas from
144 *gp130^{F/F}* mice were isolated from the stomach, washed in PBS, roughly minced and incubated in
145 digestion buffer (Dispase I (125µg/ml), Collagenase IV (75U/ml) and DMEM+2.5% FCS) at 37°C
146 until epithelial fragments dissociate from tumor bulk. Dissociated cells were passed through a
147 70µM cell strainer, counted, centrifuged and resuspended in Matrigel. *In vitro* Cre recombinase
148 was activated by treating gastric organoid cultures with 100nM 4-hydroxytamoxifen (4-OHT) as
149 previously described [31]. R-Spondin and Wnt conditioned medium were withdrawn from
150 *Tff1Cre⁺;Apc^{fl/fl}* organoid cultures following 4-OHT treatment. Differential interference contrast
151 (DIC) images were captured as Z-sections and final image generated as previously described
152 [20, 32].

153

154 **RNA extraction and analysis**

155 Gastric glands were homogenized in TRizol and total RNA purified, DNase treated, quantified
156 and subjected to quantitative reverse transcriptase PCR (qRT-PCR). qRT-PCR and calculating
157 gene expression levels relative to the house-keeping gene 18S ($2^{-\Delta\Delta CT}$) were performed as
158 previously described [16].

159

160 **MTT assay**

161 Following treatment, gastric organoids were mechanically dissociated, washed with ADF,
162 resuspended in fresh Matrigel and seeded in a flat bottom 96 well tissue culture plate for
163 enumeration using the MTT assay performed exactly as we previously described [19, 20].

164

165 **Cell culture and transfection**

166 Human gastric cancer cell lines (MKN28, MKN74, MKN7, MKN1, AGS and MKN45) were
167 maintained in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal calf serum (FCS)
168 (Invitrogen) and 1% penicillin/streptomycin (Invitrogen) and L-Glutamine (Invitrogen) and were
169 not taken past passage 15 for experimental use. All cells were tested for Mycoplasma,
170 authenticated and cultured at 37°C in 5% CO₂. Gastric cancer cells were transfected with Short-

171 hairpin RNA (shRNA) and expression constructs designed to knockdown and stably express
172 FZD7 respectively, as previously described [16, 33] or MSCV-MYC from Addgene (18119).

173

174 **Soft agar colony assay**

175 Cells were cultured in 60mm tissue culture dishes until 50% confluency and transfected with 5µg
176 of plasmid DNA using Lipofectamine LTX (Invitrogen) following manufacturer's instructions. After
177 48hrs incubation, cells were washed in PBS, detached using trypsin, resuspended
178 RPMI+10%FCS, counted and mixed with pre-warmed 1% agar/RPMI culture medium to a final
179 concentration of 500 cells/well of a 6-well plate. Once agar/cell suspensions solidified, cultures
180 were overlaid with RPMI+10% FCS culture medium and incubated at 37°C in 5% CO₂ for 14 days.
181 For Wnt inhibition experiments, cells were treated with OMP-18R5 (10µg/ml), IWP-2 (10µM) [34]
182 or vehicle control (2.5%DMSO+IgG) 3 days after plating. Treatments were removed and replaced
183 every 4 days over the 2 weeks. Cells were fixed in 4%PFA and stained with crystal violet and
184 colonies consisting of ≥50 cells scored and imaged.

185

186 **Genomic recombination PCR**

187 Conventional PCR to detect the *Fzd7* and *Apc* mutant alleles following recombination in genomic
188 DNA extracted from compound transgenic mice was performed as previously described [20, 35].
189 See also supplementary experimental procedures.

190

191 **Luciferase assay**

192 Cells were cultured in 24-well tissue culture plates until 50% confluency and transfected with a
193 total of 1µg plasmid DNA/well (500ng of SuperTOPflash or SuperFOPflash TCF reporter plasmids
194 expressing firefly luciferase [36], plus 500ng of either "control" or "treatment" DNA, plus 2ng of
195 renilla luciferase plasmid to normalize transfection efficiency). Cells were transfected using
196 Lipofectamine LTX with Plus reagent (Invitrogen) according to manufacturer's instructions. Cells
197 were harvested 48hr later and analysed using the dual luciferase reporter assay system
198 (Promega). Ratio of luciferase/renilla reporter activity was calculated and results expressed
199 relative to control cultures.

200

201 **Analysis of gastric adenocarcinoma genomic dataset**

202 Analysis of somatic mutations and copy number alterations (CNA) for a panel of 21 Wnt pathway
203 genes was performed on the TCGA stomach adenocarcinoma dataset [37] using the cBioPortal

204 platform [38]. Only samples with sequencing and CNA data were assessed across all molecular
205 subtypes, n = 287.

206

207 **Statistical analysis**

208 Data are expressed as mean \pm SEM, where mean represents number of mice (≥ 3 per genotype)
209 or number of independent experiments (≥ 3). Statistical tests used are Mann-Whitney with Prism7
210 (GraphPad software) where *P* values of ≤ 0.05 were considered significant. Heatmap generated
211 in R version 3.0.2 using the *heatmap* function in the stats base package. Raw Ct values were
212 transformed to delta Ct values using $\beta 2M$ as housekeeping gene.

213

214 **Results**

215 **Gastric cancer cells require cell intrinsic Wnt signaling for growth**

216 Gastric cancer, like many malignancies, is genetically heterogeneous, which complicates
217 identifying non-redundant signaling pathways suitable for targeted therapy. To investigate the
218 expression of Fzd receptors, which transmit oncogenic Wnt signals, we performed qRT-PCR for
219 all 10 mammalian Fzd genes on a panel of human GC cell lines. Several Fzd receptors were
220 abundantly expressed, including *FZD7* (Figs. 1A, B and Supplementary Fig. S1A-D), suggesting
221 these might be attractive therapeutic targets. Although the pan-Fzd antibody, OMP-18R5
222 (Vanticumab) has shown efficacy in several solid cancer types [39], its therapeutic potential for
223 GC has not been explored. MKN28 (*APC* mutant), MKN74 (*APC* mutant) and MKN45 (*APC* wild-
224 type) GC cells treated with OMP-18R5 formed significantly fewer anchorage-independent
225 colonies compared to vehicle control treated cells (Figs. 1C, D and Supplementary Fig. S1E). Of
226 note, MKN28 and MKN45 cells grown as conventional 2D monolayers do not show growth
227 inhibition following OMP-18R5 treatment (Supplementary Fig.1F and G), which highlights the
228 importance of testing drug efficacy in conditions that better mimic tumor biology. This suggests
229 that cell intrinsic Wnt ligands are required for the 3D-growth of GC cells, which we confirmed by
230 treatment with IWP-2, which prevents Wnt secretion [40] (Figs. 1C and D). TOPflash assays and
231 qRT-PCR demonstrate that either IWP-2 or OMP-18R5 treatment inhibit Wnt signaling in GC cells
232 (Figs. 1E-H). These data demonstrate cell intrinsic secretion of Wnt ligands and Fzd receptor
233 availability are required for the sustained growth of GC cells. To determine whether Fzd regulates
234 the growth of established gastric tumors, MKN28 and MKN45 cells were subcutaneously injected
235 into the hind flanks of nude mice and allowed to develop into palpable gastric tumors. Compared
236 to vehicle control treated gastric tumor xenografts, OMP-18R5 treated mice had significantly
237 smaller gastric tumors (Supplementary Figs. 2A-D), which demonstrates Fzd inhibition is sufficient

238 to block the initiation (Figs 1C and D) and progression (Supplementary Figs. 2A-D) of human
239 gastric cancer cells.

240

241 **Inhibiting Fzd receptors limits gastric tumorigenesis in vivo**

242 We next utilised the well-characterised *gp130^{F/F}* mouse-model of intestinal-type gastric
243 tumorigenesis [29, 41], which develop prominent antral lesions with adenomatous hyperplasia to
244 explore the relative expression of Fzd receptors. Compared to normal gastric epithelium,
245 upregulation of several Fzds was observed in *gp130^{F/F}* gastric adenomas (Figs. 2A-C), supporting
246 expression levels observed in human GC cells (Figs. 1A, B, and Supplementary Figs. S1A-D).
247 Expression of Wnt ligands and target genes are also increased in *gp130^{F/F}* gastric adenomas
248 compared to non-adenoma gastric epithelium (Figs. 2A-C, Table S1). To determine if Fzd
249 inhibition could also reduce the growth of antral gastric adenomas *in vivo*, we treated 8-week-old
250 *gp130^{F/F}* mice, which at this age have small antral gastric adenomas (Supplementary Fig. S2E),
251 with OMP-18R5 twice a week for 30 days, following published protocols (Supplementary Fig. S3A)
252 [39]. Gastric adenomas were significantly smaller and fewer in OMP-18R5-treated *gp130^{F/F}* mice
253 compared to vehicle control treated mice (Figs. 2D-F), which was associated with a significant
254 reduction in the expression of Wnt target genes and cell proliferation (PCNA IHC) (Figs. 2G-J).
255 As previously reported [39], no toxicity was observed in OMP-18R5-treated mice, which displayed
256 consistent bodyweight, no signs of morbidity and no reduction in proliferation of normal non-
257 adenoma gastric epithelial cells for the duration of treatment (Supplementary Figs. S3B-D). These
258 data strongly suggest Fzd receptors are rate-limiting for the growth of gastric adenomas *in vivo*,
259 and in human GC cells *in vitro*. Given that Wnts and Fzds can be expressed by non-epithelial
260 cells, we established gastric organoids from *gp130^{F/F}* antral adenomas using defined culture
261 conditions to determine if the anti-growth effects observed in *gp130^{F/F}* mice following OMP-18R5
262 treatment was systemic or cell intrinsic. *gp130^{F/F}* gastric adenoma organoids treated with OMP-
263 18R5 or IWP-2 displayed reduced viability (MTT assay) and growth compared to vehicle control
264 treated organoids (Figs. 2K-M). This data confirms that Wnt ligands and Fzd receptors are
265 required cell intrinsically for the growth of gastric adenoma cells *ex vivo*.

266

267 **Targeted FZD7 knockdown reduces gastric cancer colony formation**

268 Inhibition of cell growth following OMP-18R5 treatment suggest that one of several Fzds targeted
269 by OMP-18R5 (FZD1, 2, 5, 7 and 8) is responsible for transmitting Wnt signals to GC cells. Gene
270 expression analysis narrows this down to *FZD2* and/or *FZD7*, as *FZD1*, *FZD5* and *FZD8* are
271 undetectable in these cell lines (Figs. 1A and B). We have previously shown that Fzd2 is unable

272 to compensate for the loss of *Fzd7* in the intestinal epithelium [20], which may indicate *Fzd7* plays
273 a predominant role in Wnt signal transmission in gastric tissue. Indeed, *FZD7* is commonly
274 upregulated in a variety of different cancer types, including gastric cancer, which is associated
275 with poor clinical outcome [24, 42]. To determine the specific requirement of *FZD7* for the growth
276 of human GC cells we performed colony formation assays. Cells transfected with *FZD7*-targeted
277 shRNA (sh*FZD7*) [16] had a marked decrease in colony growth, compared to scrambled shRNA
278 (shSCRAM) or empty vector (EV) controls (Figs. 3A and B), associated with decreased Wnt
279 signaling (Figs. 3C and D). These data suggest that *Fzd7* is the predominant Wnt receptor
280 transmitting oncogenic Wnt signaling in GC cells. Importantly, growth inhibition following *FZD7*-
281 knockdown was rescued by co-transfection with a full-length *FZD7* expression construct [33],
282 demonstrating the specificity of the shRNA and *FZD7*-regulated growth in human GC cells
283 (Supplementary Figs. S4A and B).

284

285 **Conditional deletion of *Fzd7* from *gp130^{F/F}* gastric tumors reduces cell proliferation**

286 To determine the functional requirement of *Fzd7* for gastric adenoma growth *in vivo*, we
287 conditionally deleted *Fzd7* in the gastric adenomas of 8-week old *Tff1Cre^{ERT2/+};gp130^{F/F};Fzd7^{fl/fl}*
288 mice (*Cre⁺;gp130^{F/F};Fzd7^{fl/fl}*) (Supplementary Fig. S4C), which allows robust recombination in
289 these adenomas [25]. Tamoxifen injected *Cre⁺;gp130^{F/F};Fzd7^{fl/fl}* mice developed significantly
290 smaller and fewer antral gastric adenomas than their Cre-negative (*Cre⁻;gp130^{F/F};Fzd7^{fl/fl}*)
291 tamoxifen-treated littermates (Figs. 3E-G and Supplementary Fig. S4D), supporting our previous
292 *in vitro* experiments demonstrating *FZD7* inhibition is sufficient to block gastric adenoma growth
293 (Figs. 3A-D).

294

295 ***Fzd7* deficient cells are retained in gastric tumors and fail to proliferate**

296 The growth of *gp130^{F/F}* gastric adenomas requires Stat3 [43]. Therefore we performed p-Stat3
297 IHC and *Socs3* qRT-PCR which identified no alterations in Stat3 activity, and did not cause the
298 reduced growth of gastric adenomas in *Cre⁺;gp130^{F/F};Fzd7^{fl/fl}* mice (Figs. 4A and B). This identifies
299 that *Fzd7*-mediated Wnt signaling is rate-limiting for Stat3-driven gastric adenomas, which have
300 no Wnt-activating mutations. Deletion of *Fzd7* in normal, non-transformed gastric epithelium
301 causes repopulation with *Fzd7*-proficient cells [19]. To monitor if repopulation occurs in
302 *Cre⁺;gp130^{F/F};Fzd7^{fl/fl}* adenomas, we performed PCR for the recombined *Fzd7* floxed allele
303 (*Fzd7^A*), which we have previously shown is lost during repopulation in the normal gastric
304 epithelium following *Fzd7* deletion [19]. However, in gastric adenomas of *Cre⁺;gp130^{F/F};Fzd7^{fl/fl}*
305 mice 30 days post tamoxifen, we detect robust recombination of the *Fzd7^A* allele, demonstrating

306 that *Fzd7* deleted cells are retained in these adenomas (Fig. 4C). In support, the expression of
307 *Fzd7* and many Wnt pathway components and target genes remain low in these adenomas (Fig.
308 4D, Supplementary Fig. S4E and Table S1). This suggests that the mechanism underlying smaller
309 gastric adenomas following *Fzd7* deletion is due to retention of *Fzd7*-deficient cells in the
310 adenoma that are unable to respond to proliferative Wnt signals, and thus fail to proliferate (Fig.
311 4E). To investigate this further, we performed IHC on serial sections to detect recombined (β -gal⁺,
312 *Fzd7* deleted) cells and proliferating cells (PCNA⁺) in *Cre*⁺;*gp130*^{F/F};*Fzd7*^{fl/fl};*LacZ* mice and
313 observed a marked co-localisation of non-proliferative (PCNA⁻) cells with recombined cells (β -
314 gal⁺) (Fig. 4F).

315
316 To monitor cellular changes following *Fzd7* deletion in *Cre*⁺;*gp130*^{F/F};*Fzd7*^{fl/fl} mice, IHC for
317 apoptosis (Caspase-3) and differentiation (Muc5a and Gastrin) was performed (Supplementary
318 Fig. S4F). Muc5a⁺ and Gastrin⁺ cells were increased following *Fzd7* deletion in
319 *Cre*⁺;*gp130*^{F/F};*Fzd7*^{fl/fl} mice compared to *Fzd7*-proficient gastric adenomas (*Cre*⁻;*gp130*^{F/F};*Fzd7*^{fl/fl}).
320 This also suggests that gastric adenomas do not repopulate following *Fzd7* deletion, as
321 repopulation in the normal gastric epithelium following *Fzd7* deletion is associated with reduced
322 cell differentiation [19]. No change in the frequency of Caspase-3⁺ cells was observed
323 (Supplementary Fig. S4D), indicating that deletion of *Fzd7* from adenoma cells does not trigger
324 apoptosis.

325

326 **Cell intrinsic Wnt signaling via Fzd7 is required for Wnt-driven gastric adenomas**

327 The *gp130*^{F/F} mice and MKN45 GC cells are wild-type for *APC*, and have no known Wnt-activating
328 mutations, suggesting that targeting *Fzd7* may be effective in gastric adenomas and GC cells
329 without mutations to the Wnt pathway. However, some of the GC cell lines that responded to *Fzd*
330 therapy (MKN28 and MKN74) have mutant *APC* (<https://portals.broadinstitute.org/ccle>),
331 suggesting that *Fzd* therapies can be effective in gastric adenomas with and without mutant *APC*.
332 In silico analysis of GC patient datasets identify mutations in several genes that regulate Wnt
333 signaling, demonstrating that this pathway is aberrantly activated in GC (Supplementary Fig.
334 S5A). To functionally investigate this, gastric organoids established from *Tff1Cre*^{ERT2/+};*Apc*^{fl/fl}
335 (*Cre*⁺;*Apc*^{fl/fl}) mice were treated with tamoxifen, to truncate *Apc*, and showed significant increase
336 in growth and proliferation (Fig. 5A), which was confirmed by Ki-67 staining and increased cell
337 viability (MTT assay) (Figs. 5A-C). A concordant increase in Wnt target gene expression was
338 observed in hyperproliferative *Apc* mutant organoids (Fig. 5D). Treatment of *Apc* mutant
339 organoids with IWP-2 or OMP-18R5 prevented upregulation of the Wnt pathway and blocked

340 organoid proliferation (Figs. 5A-D), demonstrating that cell intrinsic Wnt secretion and Fzd
341 receptors are required for gastric cells to activate Wnt signaling and regulate growth, even after
342 mutation of *Apc* (Figs. 5A-D).

343
344 *Fzd7* expression was increased in *Apc* mutant gastric organoids and subsequently downregulated
345 in IWP-2 or OMP-18R5 treated organoids (Fig. 5E), therefore we examined whether *Fzd7* is
346 responsible for transmitting Wnt signaling in *Apc* mutant gastric adenoma cells *in vivo*. 30 days
347 following tamoxifen, *Cre*⁺;*Apc*^{fl/fl} mice developed multiple, large intestinal-type gastric adenomas
348 with extensive hyperplasia in the antral stomach (Figs. 6A and B), which were not observed in
349 tamoxifen-treated *Cre*⁻;*Apc*^{fl/fl} mice (Fig. 6A). Remarkably, co-recombination of *Apc* and *Fzd7*
350 alleles in *Cre*⁺;*Apc*^{fl/fl};*Fzd7*^{fl/fl} mice inhibited the ability of *Apc* mutant cells to develop antral
351 adenomas (Figs. 6A and B). Gastric adenomas of *Cre*⁺;*Apc*^{fl/fl};*Fzd7*^{fl/fl} mice had significantly less
352 PCNA⁺ cells compared to *Cre*⁺;*Apc*^{fl/fl} mice (Figs. 6A and C). In common with *gp130*^{F/F} tumors,
353 deletion of *Fzd7* in *Apc* deficient gastric adenomas also results in retention of *Fzd7*-deficient cells
354 as monitored by expression of the *Fzd7*^Δ allele (Fig. 6D).

355
356 As expected, Wnt signaling is increased in gastric adenomas of *Cre*⁺;*Apc*^{fl/fl} mice, however, Wnt
357 signaling is not elevated in the non-adenoma antral epithelium of *Cre*⁺;*Apc*^{fl/fl};*Fzd7*^{fl/fl} mice (Fig.
358 6E). This is supported by IHC for the surrogate markers of active Wnt signaling, β-catenin and
359 Myc (Supplementary Fig. S6A). IHC revealed a decrease in Muc5a⁺ and Gastrin⁺ cells following
360 *Apc* mutation (Supplementary Fig. S6B), while tamoxifen-treated *Cre*⁺;*Apc*^{fl/fl};*Fzd7*^{fl/fl} mice display
361 a modest restoration of mucus-secreting and gastrin-producing cells, similar to that observed in
362 *Cre*⁺;*gp130*^{F/F};*Fzd7*^{fl/fl} mice (Supplementary Fig. S4D). Collectively, these data demonstrate that
363 *Apc*-mutant gastric phenotypes require functional *Fzd7*.

364

365 **Fzd7-dependant Myc expression is required for the growth of gastric adenomas.**

366 The transcription factor c-Myc is a well-characterised β-catenin/TCF target gene in the
367 gastrointestinal tract as c-Myc is required for all intestinal tumor phenotypes following *Apc*-
368 mediated activation of Wnt signaling [35]. Myc is upregulated in our gastric adenoma mouse
369 models and human GC cell lines, and inhibition of *Fzd7* prevents this upregulation (Figs. 2H, 3C,
370 4D, 5D and 6E). Conditional deletion of c-Myc in *Tff1Cre*^{ERT2/+};*Apc*^{fl/fl};*c-Myc*^{fl/fl} (*Cre*⁺;*Apc*^{fl/fl};*Myc*^{fl/fl})
371 mice showed complete absence of antral adenoma formation and Wnt activation compared to
372 *Cre*⁺;*Apc*^{fl/fl} mice (Supplementary Fig. S7), indicating *Fzd7*-dependant expression of Myc is
373 required for the growth of *Apc* mutant gastric adenomas.

374 To determine whether elevated levels of MYC can rescue GC cell growth suppression following
375 *FZD7* knockdown, GC cells were co-transfected with FZD7shRNA and MSCV-MYC expression
376 plasmids and grown as colonies in soft agar for 2 weeks. Compared to control (EV) transfected
377 cells, co-transfected cells (FZD7shRNA and MSCV-MYC) showed no difference in the number of
378 colonies formed (Supplementary Fig. S7G-I), which suggests that overexpression of MYC is able
379 to rescue the growth suppressive effects of FZD7 knockdown in GC cells.

380

381 **Discussion**

382 Expression of Fzd receptors is deregulated in several cancers, including gastric cancer [4, 21,
383 42]. Here we show for the first time that Fzd receptors are rate-limiting for the growth of gastric
384 adenomas *in vivo*. We further elucidate that Fzd7 is the predominant Wnt receptor transmitting
385 cell-intrinsic Wnt signals in human GC cells.

386

387 *In vitro* studies have shown that targeted inhibition of Fzd is sufficient to block growth of GC cells
388 [24, 44]. However, it is well documented that *in vitro* studies do not fully recapitulate the complex
389 cellular and molecular interactions present in tumors [45]. Here, we demonstrate that gastric
390 adenomas require Fzd7 for optimal growth using genetic and pharmacological strategies in two
391 independent mouse models. Our findings support our previous work [39] demonstrating that
392 targeting multiple Fzd receptors blocks the growth of several different cancers, which we now
393 extend to GC. Using *ex-vivo* adenoma-derived organoids we demonstrate these anti-growth
394 effects are cell intrinsic as OMP-18R5 blocks the growth of gastric adenoma-derived organoids in
395 the absence of immune or stromal cells.

396

397 As previously observed in the normal gastric epithelium [19], genetic inhibition of *Fzd7* in gastric
398 adenomas induces upregulation of other *Fzd* genes (Table S1), however, these are insufficient to
399 compensate and promote gastric adenoma growth. This suggests that specific targeting of Fzd7
400 is an attractive therapeutic strategy for the treatment of gastric cancer.

401

402 Deletion of *Fzd7* in the normal gastric epithelium triggers repopulation [19] which could be a
403 possible explanation for why *Fzd7*-deficient gastric adenomas are smaller. Epithelial repopulation
404 is an effective tissue mechanism that helps the gastric epithelium to survive the harsh conditions
405 of the stomach. Here we show that repopulation is not preserved in gastric adenomas, which
406 contain aberrant cell signaling and tissue architecture, and therefore *Fzd7*-deficient cells remain
407 in the adenoma but are unable to respond to Wnt signals and thus do not proliferate.

408 One feature of inflammation-associated tumors in the gastrointestinal tract is phosphorylated
409 Stat3 (p-Stat3), which regulates many cancer hallmarks [43]. Gastric adenomas in *gp130^{FF}* mice
410 do not harbor any Wnt-activating mutations [41], however, they display high levels of Wnt
411 signaling. Stat-3 has been shown to activate Wnt signaling, which would allow pathway activation
412 in the absence of Wnt mutations in *gp130^{FF}* adenomas [46, 47]. Indeed, Wnt and gp130/Stat3
413 signaling operate in parallel during gastric tumorigenesis as active p-Stat3 levels remain high in
414 *Fzd7* deleted adenomas, demonstrating that Wnt/Fzd7 signaling is rate-limiting for Stat3-driven
415 gastric adenomas. Similarly, mTORC1 signaling is also rate-limiting for *gp130^{FF}* adenoma growth
416 independent of Stat3 [41].

417
418 Recent large-scale sequencing of human gastric tumors has identified environmental and genetic
419 factors associated with increased pathology, which include aberrant Wnt signaling [48-50].
420 Importantly, these genomic studies are yet to be validated with functional interrogation *in vivo*,
421 which are essential to understand the therapeutic potential of targeting Wnt signaling in gastric
422 cancer [21]. We and others have demonstrated that *Fzd7* inhibition is sufficient to block Wnt
423 signaling in cells with mutant *APC* [17, 51]. Interestingly, ~37% of *APC* mutant gastric tumors are
424 mutant for *RNF43* (regulates Fzd on the cell surface [12]), demonstrating that Fzd is deregulated
425 in a subset of *APC* mutant gastric tumors (<http://www.cbioportal.org/>). Interestingly *RNF43* and
426 *APC* mutations are mutually exclusive in colon tumors suggesting that CRC and GC cells
427 preferentially select different Wnt mutations that confer optimal or 'just-right' levels of Wnt
428 signaling required for tumor growth [52, 53].

429
430 Furthermore, we have shown that Myc is required for the gastric adenoma phenotypes associated
431 with *Apc* mutation. These findings are reminiscent of the role played by Myc in the intestinal
432 epithelium following *Apc* mutation [35], and thus place the Wnt/Fzd7/Myc signaling axis as an
433 attractive therapeutic target for gastric cancer. Encouragingly, next generation bromodomain
434 (BET) inhibitors are effective in killing patient-derived GC cells [54]. Importantly, this provides
435 justification for testing a combination of BET and Wnt inhibitors in GC, which we have previously
436 shown is effective at blocking the growth of human colon cancer cells [55].

437
438 New generation PORCN inhibitors are in clinical trials for solid tumors, which our results show
439 may be effective in gastric cancer, however these target the secretion of all Wnt ligands.
440 Collectively, we demonstrate that targeted inhibition of Wnt receptors, specifically Fzd7, is rate-
441 limiting for the growth of gastric adenomas with and without *Apc* mutations. This provides a broad

442 scope for the application of this therapeutic strategy for the treatment of GC, with potentially less
443 side effects than targeting all Wnt secretion with PORCN inhibitors, and will directly inform clinical
444 trials to treat GC patients with OMP-18R5 (Vantictumab), which only targets 5 out of the 10 Fzd
445 family.

446
447 **Acknowledgments:** We thank Damian Neate and Jean Moselen for technical assistance. We
448 also thank John Mariadason, Cameron Nowell, Christine Wells, Trevelyan Menheniott, Matthias
449 Ernst, Stefen Glaser and Andy Giraud for gifting cell lines, plasmids, mutant mice, microscopy
450 assistance and critical discussion.

451

452 References

453

- 454 1. Guggenheim, D.E. and M.A. Shah, *Gastric cancer epidemiology and risk factors*. J Surg
455 Oncol, 2013. **107**(3): p. 230-6.
- 456 2. Blackham, A.U., et al., *Tumor regression grade in gastric cancer: Predictors and impact*
457 *on outcome*. J Surg Oncol, 2016. **114**(4): p. 434-9.
- 458 3. Jemal, A., et al., *Global cancer statistics*. CA Cancer J Clin, 2011. **61**(2): p. 69-90.
- 459 4. Ueno, K., et al., *Frizzled homolog proteins, microRNAs and Wnt signaling in cancer*. Int J
460 Cancer, 2013. **132**(8): p. 1731-40.
- 461 5. Janda, C.Y., et al., *Structural basis of Wnt recognition by Frizzled*. Science, 2012.
462 **337**(6090): p. 59-64.
- 463 6. Takada, R., et al., *Monounsaturated fatty acid modification of Wnt protein: its role in Wnt*
464 *secretion*. Dev Cell, 2006. **11**(6): p. 791-801.
- 465 7. Niehrs, C., *The complex world of WNT receptor signalling*. Nat Rev Mol Cell Biol, 2012.
466 **13**(12): p. 767-79.
- 467 8. Nusse, R. and H. Clevers, *Wnt/beta-Catenin Signaling, Disease, and Emerging*
468 *Therapeutic Modalities*. Cell, 2017. **169**(6): p. 985-999.
- 469 9. MacDonald, B.T. and X. He, *Frizzled and LRP5/6 receptors for Wnt/beta-catenin signaling*.
470 Cold Spring Harb Perspect Biol, 2012. **4**(12).
- 471 10. Yu, J., et al., *Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is*
472 *associated with poor survival in gastric cancer*. Cancer, 2009. **115**(1): p. 49-60.
- 473 11. Nojima, M., et al., *Frequent epigenetic inactivation of SFRP genes and constitutive*
474 *activation of Wnt signaling in gastric cancer*. Oncogene, 2007. **26**(32): p. 4699-713.
- 475 12. Koo, B.K., et al., *Tumour suppressor RNF43 is a stem-cell E3 ligase that induces*
476 *endocytosis of Wnt receptors*. Nature, 2012. **488**(7413): p. 665-9.
- 477 13. Wang, K., et al., *Whole-genome sequencing and comprehensive molecular profiling*
478 *identify new driver mutations in gastric cancer*. Nat Genet, 2014. **46**(6): p. 573-82.
- 479 14. Wang, B., et al., *Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression*
480 *suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling*.
481 J Gastroenterol, 2013. **48**(7): p. 798-808.
- 482 15. Suzuki, H., et al., *Epigenetic inactivation of SFRP genes allows constitutive WNT signaling*
483 *in colorectal cancer*. Nat Genet, 2004. **36**(4): p. 417-22.
- 484 16. Vincan, E., et al., *Frizzled-7 dictates three-dimensional organization of colorectal cancer*
485 *cell carcinoids*. Oncogene, 2007. **26**(16): p. 2340-52.

- 486 17. Vincan, E., et al., *Frizzled-7 receptor ectodomain expression in a colon cancer cell line*
487 *induces morphological change and attenuates tumor growth*. *Differentiation*, 2005. **73**(4):
488 p. 142-53.
- 489 18. Voloshanenko, O., et al., *Wnt secretion is required to maintain high levels of Wnt activity*
490 *in colon cancer cells*. *Nat Commun*, 2013. **4**: p. 2610.
- 491 19. Flanagan, D.J., et al., *Loss of the Wnt receptor Frizzled7 in the gastric epithelium is*
492 *deleterious and triggers rapid repopulation in vivo*. *Dis Model Mech*, 2017.
- 493 20. Flanagan, D.J., et al., *Frizzled7 Functions as a Wnt Receptor in Intestinal Epithelial*
494 *Lgr5(+) Stem Cells*. *Stem Cell Reports*, 2015. **4**(5): p. 759-767.
- 495 21. Flanagan, D.J., E. Vincan, and T.J. Phesse, *Winding back Wnt signalling: potential*
496 *therapeutic targets for treating gastric cancers*. *Br J Pharmacol*, 2017.
- 497 22. Kirikoshi, H., H. Sekihara, and M. Katoh, *Up-regulation of Frizzled-7 (FZD7) in human*
498 *gastric cancer*. *Int J Oncol*, 2001. **19**(1): p. 111-5.
- 499 23. Zhao, C.M., et al., *Denervation suppresses gastric tumorigenesis*. *Sci Transl Med*, 2014.
500 **6**(250): p. 250ra115.
- 501 24. Li, G., et al., *Frizzled7 Promotes Epithelial-to-mesenchymal Transition and Stemness Via*
502 *Activating Canonical Wnt/beta-catenin Pathway in Gastric Cancer*. *Int J Biol Sci*, 2018.
503 **14**(3): p. 280-293.
- 504 25. Thiem, S., et al., *Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent*
505 *Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model*.
506 *Cancer Res*, 2016. **76**(8): p. 2277-87.
- 507 26. Shibata, H., et al., *Rapid colorectal adenoma formation initiated by conditional targeting*
508 *of the Apc gene*. *Science*, 1997. **278**(5335): p. 120-3.
- 509 27. Bettess, M.D., et al., *c-Myc is required for the formation of intestinal crypts but dispensable*
510 *for homeostasis of the adult intestinal epithelium*. *Mol Cell Biol*, 2005. **25**(17): p. 7868-78.
- 511 28. Soriano, P., *Generalized lacZ expression with the ROSA26 Cre reporter strain*. *Nat Genet*,
512 1999. **21**(1): p. 70-1.
- 513 29. Tebbutt, N.C., et al., *Reciprocal regulation of gastrointestinal homeostasis by SHP2 and*
514 *STAT-mediated trefoil gene activation in gp130 mutant mice*. *Nat Med*, 2002. **8**(10): p.
515 1089-97.
- 516 30. Broutier, L., et al., *Culture and establishment of self-renewing human and mouse adult*
517 *liver and pancreas 3D organoids and their genetic manipulation*. *Nat Protoc*, 2016. **11**(9):
518 p. 1724-43.
- 519 31. Flanagan, D.J., et al., *Isolation and Culture of Adult Intestinal, Gastric, and Liver*
520 *Organoids for Cre-recombinase-Mediated Gene Deletion*. *Methods Mol Biol*, 2016.
- 521 32. Phesse, T.J., et al., *Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-beta-*
522 *catenin-mediated intestinal tumor growth and regeneration*. *Sci Signal*, 2014. **7**(345): p.
523 ra92.
- 524 33. Sagara, N., et al., *Molecular cloning, differential expression, and chromosomal localization*
525 *of human frizzled-1, frizzled-2, and frizzled-7*. *Biochem Biophys Res Commun*, 1998.
526 **252**(1): p. 117-22.
- 527 34. Mo, M.L., et al., *Inhibition of the Wnt palmitoyltransferase porcupine suppresses cell*
528 *growth and downregulates the Wnt/beta-catenin pathway in gastric cancer*. *Oncol Lett*,
529 2013. **5**(5): p. 1719-1723.
- 530 35. Sansom, O.J., et al., *Myc deletion rescues Apc deficiency in the small intestine*. *Nature*,
531 2007. **446**(7136): p. 676-679.
- 532 36. Veeman, M.T., et al., *Zebrafish prickles, a modulator of noncanonical Wnt/Fz signaling,*
533 *regulates gastrulation movements*. *Curr Biol*, 2003. **13**(8): p. 680-5.
- 534 37. Cancer Genome Atlas Research, N., *Comprehensive molecular characterization of gastric*
535 *adenocarcinoma*. *Nature*, 2014. **513**(7517): p. 202-9.

- 536 38. Cerami, E., et al., *The cBio cancer genomics portal: an open platform for exploring*
537 *multidimensional cancer genomics data*. *Cancer Discov*, 2012. **2**(5): p. 401-4.
- 538 39. Gurney, A., et al., *Wnt pathway inhibition via the targeting of Frizzled receptors results in*
539 *decreased growth and tumorigenicity of human tumors*. *Proc Natl Acad Sci U S A*, 2012.
540 **109**(29): p. 11717-22.
- 541 40. Chen, B., et al., *Small molecule-mediated disruption of Wnt-dependent signaling in tissue*
542 *regeneration and cancer*. *Nat Chem Biol*, 2009. **5**(2): p. 100-7.
- 543 41. Thiem, S., et al., *mTORC1 inhibition restricts inflammation-associated gastrointestinal*
544 *tumorigenesis in mice*. *J Clin Invest*, 2013.
- 545 42. Pheesse, T., D. Flanagan, and E. Vincan, *Frizzled7: A Promising Achilles' Heel for*
546 *Targeting the Wnt Receptor Complex to Treat Cancer*. *Cancers (Basel)*, 2016. **8**(5).
- 547 43. Bollrath, J., et al., *gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival*
548 *and Cell-Cycle Progression during Colitis-Associated Tumorigenesis*. *Cancer Cell*, 2009.
549 **15**(2): p. 91-102.
- 550 44. Tomizawa, M., et al., *Gastric cancer cell proliferation is suppressed by frizzled-2 short*
551 *hairpin RNA*. *Int J Oncol*, 2015. **46**(3): p. 1018-24.
- 552 45. Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: the next generation*. *Cell*, 2011.
553 **144**(5): p. 646-74.
- 554 46. Ahmad, R., et al., *Loss of claudin-3 expression induces IL6/gp130/Stat3 signaling to*
555 *promote colon cancer malignancy by hyperactivating Wnt/beta-catenin signaling*.
556 *Oncogene*, 2017. **36**(47): p. 6592-6604.
- 557 47. Lin, J., X. Wang, and R.I. Dorsky, *Progenitor expansion in apc mutants is mediated by*
558 *Jak/Stat signaling*. *BMC Dev Biol*, 2011. **11**: p. 73.
- 559 48. TCGA, *Comprehensive molecular characterization of gastric adenocarcinoma*. *Nature*,
560 2014. **513**(7517): p. 202-9.
- 561 49. Wang, K., et al., *Whole-genome sequencing and comprehensive molecular profiling*
562 *identify new driver mutations in gastric cancer*. *Nat Genet*, 2014. **46**(6): p. 573-82.
- 563 50. Cristescu, R., et al., *Molecular analysis of gastric cancer identifies subtypes associated*
564 *with distinct clinical outcomes*. *Nat Med*, 2015. **21**(5): p. 449-56.
- 565 51. Ueno, K., et al., *Frizzled-7 as a potential therapeutic target in colorectal cancer*. *Neoplasia*,
566 2008. **10**(7): p. 697-705.
- 567 52. Albuquerque, C., et al., *The 'just-right' signaling model: APC somatic mutations are*
568 *selected based on a specific level of activation of the beta-catenin signaling cascade*. *Hum*
569 *Mol Genet*, 2002. **11**(13): p. 1549-60.
- 570 53. Lamlum, H., et al., *The type of somatic mutation at APC in familial adenomatous polyposis*
571 *is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit'*
572 *hypothesis*. *Nat Med*, 1999. **5**(9): p. 1071-5.
- 573 54. Montenegro, R.C., et al., *BET inhibition as a new strategy for the treatment of gastric*
574 *cancer*. *Oncotarget*, 2016. **7**(28): p. 43997-44012.
- 575 55. Togel, L., et al., *Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and*
576 *WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal*
577 *Cancer Cells*. *Mol Cancer Ther*, 2016. **15**(6): p. 1217-26.

578

579 **Figure Legends**

580

581 **Figure 1. Inhibition of Wnt or Fzd blocks gastric cancer cell growth.**

- 582 A. qRT-PCR for *FZD* gene expression in MKN28 gastric cancer cells. Expression shown
583 relative to housekeeper (β 2M), n=4 biological replicates.
- 584 B. qRT-PCR for *FZD* gene expression in MKN74 gastric cancer cells. Expression shown
585 relative to housekeeper (β 2M), n=4 biological replicates.
- 586 C. Quantification of cell colonies (>50 cells) from MKN28 gastric cancer cells grown in agar
587 for 2 weeks following treatment with vehicle control (2.5%DMSO+IgG), IWP-2 (10 μ M) or
588 OMP-18R5 (10 μ g/ml). Treatments were replaced every 4 days for the duration of 2 weeks.
589 Individual experiments were repeated three times. Colonies were counted with ImageJ (*=
590 $p < 0.05$, mean \pm SEM, Mann-Whitney).
- 591 D. Quantification of cell colonies (>50 cells) from MKN74 gastric cancer cells grown in agar
592 for 2 weeks following treatment with vehicle control (2.5%DMSO+IgG), IWP-2 (10 μ M) or
593 OMP-18R5 (10 μ g/ml). Treatments were replaced every 4 days for the duration of 2 weeks.
594 Individual experiments were repeated three times. Colonies were counted with ImageJ (*=
595 $p < 0.05$, mean \pm SEM, Mann-Whitney).
- 596 E. TOPflash assay on MKN28 cells treated 24hrs with DMSO, IWP-2 (10 μ M) or OMP-18R5
597 (10 μ g/ml) (**= $p < 0.005$, mean \pm SEM, n=9 biological replicates, Mann-Whitney). Individual
598 experiments were repeated three times.
- 599 F. TOPflash assay on MKN74 cells treated 24hrs with DMSO, IWP-2 (10 μ M) or OMP-18R5
600 (10 μ g/ml) (**= $p < 0.005$, mean \pm SEM, n=9 biological replicates, Mann-Whitney). Individual
601 experiments were repeated three times.
- 602 G. qRT-PCR for *CD44* in MKN28 and MKN74 cells described in E and F (mean \pm SEM, n=6
603 biological replicates, Mann-Whitney). Individual experiments were repeated twice.
- 604 H. qRT-PCR for *AXIN2* in MKN28 and MKN74 cells described in E and F (mean \pm SEM, n=6
605 biological replicates, Mann-Whitney). Individual experiments were repeated twice.
- 606

607 **Figure 2. Inhibition of Fzd receptors reduces cell intrinsic Wnt signaling and gastric**
608 **adenoma burden.**

- 609 A. qRT-PCR for Wnt ligands in *gp130^{FF}* adenomas compared to normal gastric epithelium
610 (*= $p < 0.05$, mean \pm SEM, n=4 mice, Mann-Whitney).
- 611 B. qRT-PCR for Fzd receptors in *gp130^{FF}* adenomas compared to normal gastric epithelium
612 (*= $p < 0.05$, mean \pm SEM, n=4 mice, Mann-Whitney).
- 613 C. qRT-PCR for Wnt target genes in *gp130^{FF}* adenomas compared to normal gastric
614 epithelium (*= $p < 0.05$, mean \pm SEM, n=4 mice, Mann-Whitney).
- 615 D. Whole mount images of 8-9 week old *gp130^{FF}* mice treated with control IgG or OMP-18R5
616 over the course of 30 days and harvested. Black and white arrows show gastric tumors.
- 617 E. Weights of gastric adenomas from mice described in D (**= $p < 0.001$, mean \pm SEM, n=9
618 mice, Mann-Whitney).
- 619 F. Quantification of gastric adenomas in mice described in D (**= $p < 0.001$, mean \pm SEM,
620 n=9 mice, Mann-Whitney).
- 621 G. qRT-PCR for Fzd receptors in mice described in D (**= $p < 0.005$, mean \pm SEM, n=9 mice,
622 Mann-Whitney).
- 623 H. qRT-PCR for Wnt target genes in mice described in D (**= $p < 0.005$, mean \pm SEM, n=9
624 mice, Mann-Whitney).

- 625 I. Immunohistochemistry for PCNA on adenomas sections from mice described in D. Scale
626 bars = 100µm.
- 627 J. Quantification of PCNA⁺ cells from adenomas sections described in I (*= p<0.05, mean
628 ±SEM, n=4 mice, Mann-Whitney).
- 629 K. Representative DIC images of *gp130^{F/F}* adenoma-derived organoids treated with vehicle
630 control (2.5%DMSO+IgG), IWP-2 (10µM) or OMP-18R5 (10µg/ml) and cultured for 5 days.
631 Green arrows indicate viable organoids. Red arrows indicate dying/atrophic organoids.
632 Scale bar = 200 µm
- 633 L. MTT viability assay performed on organoids described in K (*= p<0.05, mean ±SEM, n=3
634 biological replicates, Mann-Whitney).
- 635 M. Measurement (diameter) of organoids described in K. Measurements were quantified in
636 ImageJ (*= p<0.05, mean ±SEM, n=3 biological replicates, Mann-Whitney).

637
638 **Figure 3. Targeted inhibition of Fzd7 reduces gastric cancer clonogenicity and adenoma**
639 **burden.**

- 640 A. Representative DIC images of MKN28 and MKN74 cells transfected with empty vector
641 (EV), scrambled (shSCRAM) or FZD7-specific shRNA (FZD7shRNA) and grown in agar.
642 Scale bars = 200µm
- 643 B. Quantification of cell colonies from experiment described in A (*= p<0.05, mean ±SEM,
644 n=3 biological replicates, Mann-Whitney). Individual experiments were repeated twice.
- 645 C. qRT-PCR for Wnt target genes on MKN28 and MKN74 cells transfected with empty vector
646 (EV), scrambled (shSCRAM) or FZD7-specific shRNA (Fzd7shRNA) (*= p<0.05, mean
647 ±SEM, n=3 biological replicates, Mann-Whitney).
- 648 D. TOPflash assay on MKN28 and MKN74 cells described in C (***= p<0.001, mean ±SEM,
649 n=9 biological replicates, Mann-Whitney). Individual experiments were repeated three
650 times.
- 651 E. Representative images of tamoxifen-treated *Tff1Cre^{ERT2/-}* (*Cre⁻*) or *Tff1Cre^{ERT2/+}* (*Cre⁺*)
652 stomachs following *Fzd7* deletion. Black arrows indicate gastric tumors.
- 653 F. Weights of gastric adenomas per mouse described in E (**= p<0.005, mean ±SEM, n=7
654 mice, Mann-Whitney).
- 655 G. Quantification of gastric adenomas per mouse described in E (**= p<0.005, mean ±SEM,
656 n=7 mice, Mann-Whitney).

657
658 **Figure 4. Deletion of Fzd7 from gastric tumors decreases cell proliferation.**

- 659 A. Immunohistochemistry (IHC) for p-Stat3 on adenoma sections from *Fzd7^{fl/fl};gp130^{F/F}* mice
660 (*Cre⁻* or *Cre⁺*) 30 days after tamoxifen treatment. Scale bars = 100µm.
- 661 B. qRT-PCR for *Socs3* on gastric adenomas from mice described in A (*= p<0.05, mean
662 ±SEM, n=4 mice, Mann-Whitney).
- 663 C. Conventional PCR to detect recombination of *Fzd7^{fl/fl}* allele (*Fzd7^Δ*) in gastric adenomas
664 from mice described in A.
- 665 D. qRT-PCR for Wnt target genes in gastric adenomas from mice described in A (**=
666 p<0.005, mean ±SEM, n=7 mice, Mann-Whitney).
- 667 E. Quantification of PCNA⁺ cells from adenoma sections described in A (*= p<0.05, mean
668 ±SEM, n=3 mice, Mann-Whitney).
- 669 F. Representative IHC images for β-galactosidase (detecting allelic recombination) and
670 PCNA (proliferation) on serial sections from *Tff1Cre⁻;Fzd7^{fl/fl};gp130^{F/F};LacZ* or
671 *Tff1Cre⁺;Fzd7^{fl/fl};gp130^{F/F};LacZ* mice 30 days following tamoxifen. Note, yellow dashed

672 lines demarcate areas of allelic recombination, which correspond to reduced proliferation
673 and black dashed lines represent areas of non-recombined cells. Scale bars = 100µm.
674

675 **Figure 5. Wnt/Fzd inhibition reduces *Apc* mutant gastric organoid proliferation.**

- 676 A. Representative DIC and immunofluorescence images of *Tff1Cre⁻;Apc^{fl/fl}* organoids treated
677 for 24hrs with tamoxifen (tmx, 100nM), IWP-2 (10µM) or OMP-18R5 (10µg/ml). Green
678 arrows indicate hyperproliferative organoids. Red arrows indicate growth-constrained
679 organoids. Scale bars = 200µm.
- 680 B. MTT viability assay performed on organoid cultures described in A (**= p<0.001, mean
681 ±SEM, n=3 biological replicates, Mann-Whitney). Individual experiments were repeated
682 twice.
- 683 C. Measurement of organoid size (µm) from cultures described in A (**= p<0.001, mean
684 ±SEM, n=3 biological replicates, Mann-Whitney).
- 685 D. qRT-PCR for Wnt target genes on organoid cultures described in A (*= p<0.05, mean
686 ±SEM, n=3 biological replicates, Mann-Whitney).
- 687 E. qRT-PCR for Fzd receptors on organoid cultures described in A. Expression of Fzd shown
688 as Log₂ ratio.

689
690 **Figure 6. Deletion of *Fzd7* rescues gastric adenoma formation following *Apc* truncation.**

- 691 A. Representative whole mount and IHC (PCNA) on wild-type (*Tff1Cre⁻;Apc^{fl/fl}*), *Apc* mutant
692 (*Tff1Cre⁺;Apc^{fl/fl}*) and *Apc/Fzd7* mutant mice (*Tff1Cre⁺;Apc^{fl/fl};Fzd7^{fl/fl}*) 30 days following
693 tamoxifen. Black arrows indicate gastric adenomas in top panels. Scale bars = 100µm.
- 694 B. Weights of gastric adenomas from harvested mice described in A (**= p<0.005, mean
695 ±SEM, n=7 mice, Mann-Whitney).
- 696 C. Quantification of PCNA⁺ cells in adenoma sections from mice described in A (**= p<0.001,
697 mean ±SEM, n=3 mice, Mann-Whitney).
- 698 D. Conventional PCR for recombined *Fzd7* (*Fzd7^Δ*) and *Apc* (*Apc^Δ*) alleles in mice described
699 in A.
- 700 E. qRT-PCR for Wnt target genes on tamoxifen-treated mice described in A (**= p<0.005,
701 mean ±SEM, n=4 mice, Mann-Whitney).

702
703